NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

OPKO Health, Inc. (OPK) Stock Analysis

OPKO Health, Inc. (OPK) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

OPK

$1.64

+$0.03 (+1.86%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OPK with… →

OPK Key Statistics

As of Sep 4, 2026
Trading
Open
$1.59
Previous Close
$1.61
Day's Range
1.57–1.65
52-Week Range
0.98–1.73
Volume
2.35M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.50
Valuation
Market Cap
$1.22B
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
93.65
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.08
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.07
Financials (FY)
Revenue (FY)
$606.88M−14.90%
Net Income (FY)
−$225.68M
Profit marginThe share of revenue left as profit after all costs and taxes.
−12.40%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
746.33M
1-Year Return
+18.84%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
3.58M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OPK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+30.16%
2025−14.29%
2024−2.65%
2023+20.80%
2022−74.01%
2021+21.77%
2020+168.71%
2019−51.16%
2018−38.57%
2017−47.31%
2016 (partial year)−8.01%

As of September 4, 2026.

OPK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$606.88M−$225.68M−37.2%
2024$713.14M−$53.22M−7.5%
2023$863.50M−$188.86M−21.9%
2022$1.00B−$328.41M−32.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$606.88M$205.94M−$117.41M−$225.68M−37.2%
2024$713.14M$218.51M−$152.07M−$53.22M−7.5%
2023$863.50M$318.13M−$157.02M−$188.86M−21.9%
2022$1.00B$288.22M−$226.25M−$328.41M−32.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OPK Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricOPKDiagnostics & Research medianvs median
P/S ratio2.084.9958% below
Profit margin−12.40%0.00%12.4 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

OPKO Health, Inc. (OPK) carries a market capitalisation of $1.22B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 2,275.

Over the past 52 weeks the price has ranged from $0.98 to $1.73. OPK last closed at $1.64 on September 4, 2026. That is +$0.03 (+1.86%) against the previous close. The latest close sits 67.35% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $606.88M. That is −14.90% against the prior fiscal year, when revenue was $713.14M. The same year closed with a net loss of $225.68M. The reported profit margin is −12.4%. That is 12.4 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −0.07.

Across the 4 fiscal years on file, revenue moves from $1.00B in 2022 to $606.88M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 93.65. Measured against sales, the shares trade at 2.08 times revenue. On price-to-sales that is 58.28% below the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.5. Annualized volatility over the trailing 10 years is 65.98%. Over the trailing twelve months the price has returned +18.84%. Across 10 years the annualized return works out at −15.96%.

Growth & Income

No dividend is on file for OPK.

So far in 2026 the price is +30.16%. Across the complete calendar years on file, 2020 returned +168.71% and 2022 returned −74.01%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

OPKO Health, Inc. (OPK) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
OPKO Health, Inc. OPK $1.22B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. OPKO Health, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About OPKO Health, Inc.

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Visit website →